Cargando…

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates

Antibody‐drug conjugates (ADCs) are a rapidly growing therapeutic platform for the treatment of cancer. ADCs consist of a cytotoxic small molecule drug linked to an antibody to provide targeted delivery of the cytotoxic agent to the tumor. Understanding the pharmacokinetics (PK) and pharmacodynamics...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamath, Amrita V., Iyer, Suhasini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032988/
https://www.ncbi.nlm.nih.gov/pubmed/25904406
http://dx.doi.org/10.1002/bdd.1957
_version_ 1782455091538690048
author Kamath, Amrita V.
Iyer, Suhasini
author_facet Kamath, Amrita V.
Iyer, Suhasini
author_sort Kamath, Amrita V.
collection PubMed
description Antibody‐drug conjugates (ADCs) are a rapidly growing therapeutic platform for the treatment of cancer. ADCs consist of a cytotoxic small molecule drug linked to an antibody to provide targeted delivery of the cytotoxic agent to the tumor. Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of ADCs is crucial in their design to optimize dose and regimen, to maximize efficacy and to minimize toxicity in patients. Significant progress has been made in recent years in this area, however, many fundamental questions still remain. This review discusses factors to consider while assessing the disposition of ADCs, and the unique challenges associated with these therapeutics. Current tools that are available and strategies to enable appropriate assessment are also discussed. © 2015 Genentech Inc. Biopharmaceutics & Drug Disposition Published by John Wiley & Sons Ltd.
format Online
Article
Text
id pubmed-5032988
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50329882016-10-03 Challenges and advances in the assessment of the disposition of antibody‐drug conjugates Kamath, Amrita V. Iyer, Suhasini Biopharm Drug Dispos Invited Reviews Antibody‐drug conjugates (ADCs) are a rapidly growing therapeutic platform for the treatment of cancer. ADCs consist of a cytotoxic small molecule drug linked to an antibody to provide targeted delivery of the cytotoxic agent to the tumor. Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of ADCs is crucial in their design to optimize dose and regimen, to maximize efficacy and to minimize toxicity in patients. Significant progress has been made in recent years in this area, however, many fundamental questions still remain. This review discusses factors to consider while assessing the disposition of ADCs, and the unique challenges associated with these therapeutics. Current tools that are available and strategies to enable appropriate assessment are also discussed. © 2015 Genentech Inc. Biopharmaceutics & Drug Disposition Published by John Wiley & Sons Ltd. John Wiley and Sons Inc. 2015-06-08 2016-03 /pmc/articles/PMC5032988/ /pubmed/25904406 http://dx.doi.org/10.1002/bdd.1957 Text en © 2015 Genentech Inc. Biopharmaceutics & Drug Disposition Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Invited Reviews
Kamath, Amrita V.
Iyer, Suhasini
Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
title Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
title_full Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
title_fullStr Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
title_full_unstemmed Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
title_short Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
title_sort challenges and advances in the assessment of the disposition of antibody‐drug conjugates
topic Invited Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032988/
https://www.ncbi.nlm.nih.gov/pubmed/25904406
http://dx.doi.org/10.1002/bdd.1957
work_keys_str_mv AT kamathamritav challengesandadvancesintheassessmentofthedispositionofantibodydrugconjugates
AT iyersuhasini challengesandadvancesintheassessmentofthedispositionofantibodydrugconjugates